2012-10-10 01:06:56 - Recently published research from Global Markets Direct, "Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2012", is now available at Fast Market Research
Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM). Glioblastoma Multiforme (GBM) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
- www.fastmr.com/prod/468434_glioblastoma_multiforme_gbm_pipeline_ ..
Note*: Certain sections in the report
may be removed or altered based on the availability and relevance of data for the indicated disease.
* A snapshot of the global therapeutic scenario for Glioblastoma Multiforme (GBM).
* A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Glioblastoma Multiforme (GBM) Overview
An Overview of Pipeline Products for Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme (GBM) Therapeutics under Development by Companies
Glioblastoma Multiforme (GBM) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Glioblastoma Multiforme (GBM) Therapeutics - Products under Development by Companies
Glioblastoma Multiforme (GBM) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Glioblastoma Multiforme (GBM) Therapeutics Development
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Merck & Co., Inc.
Sangamo BioSciences, Inc.
Ark Therapeutics Group plc
Eisai Co., Ltd.
Nippon Shinyaku Co., Ltd.
Teva Pharmaceutical Industries Limited
Cell Therapeutics, Inc.
Celldex Therapeutics, Inc.
ImmunoCellular Therapeutics, Ltd.
Lixte Biotechnology Holdings, Inc.
Northwest Biotherapeutics, Inc.
Cleveland BioLabs, Inc.
Peregrine Pharmaceuticals, Inc.
PhytoMedical Technologies, Inc.
Prana Biotechnology Limited
Threshold Pharmaceuticals, Inc.
Proximagen Neuroscience plc.
Rexahn Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
INSYS Therapeutics, Inc.
Ambit Biosciences Corporation
Adnexus Therapeutics, Inc.
immatics biotechnologies GmbH
Diffusion Pharmaceuticals LLC
Arno Therapeutics, Inc.
Nobelpharma Co., Ltd.
Deciphera Pharmaceuticals, LLC
Vascular Biogenics Ltd.
Stemline Therapeutics, Inc.
BioCancell Therapeutics, Inc.
Advenchen Laboratories, LLC
Viral Genetics, Inc.
Myriad Pharmaceuticals, Inc.
NOXXON Pharma AG
TVAX Biomedical, LLC
Nexgenix Pharmaceuticals, LLC
Archer Biosciences, Inc
R&D Systems, Inc.
TAU Therapeutics, LLC
EirGen Pharma Ltd.
Ampio Pharmaceuticals, Inc.
Glioblastoma Multiforme (GBM) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
enzastaurin hydrochloride - Drug Profile
Mechanism of Action
cediranib maleate - Drug Profile
Mechanism of Action
rindopepimut - Drug Profile
Mechanism of Action
bevacizumab - Drug Profile
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.